China Drug Delivery Devices Market by Route of Applications (Cardiovascular, Oncology, Autoimmune Disorder, Pulmonary Disease, and Other), Device Type (Nasal [Inhalers, and Other], Injectable [Conventional Drug Delivery Devices, and Self-injectable Drug Delivery Devices [Prefilled Syringes, Auto Injectors, and Others], Implantable, and Others), End Users (Hospitals, Pharmacy, and Others), and Country - Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

The China drug delivery devices market size is anticipated to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the Italy moving towards value-based healthcare and rising technological advancements, growth in the biologics market.

Drugs at the action site cannot reach adequate concentrations to achieve predicted therapeutic outcomes due to poor physicochemical qualities and multi-stage biological barriers in vivo, which can lead to side effects in normal tissues and organs. For hundreds of years, Traditional Chinese Medicine (TCM) has been utilized in China to prevent and treat numerous ailments. The active ingredients are the are crucial active compounds that can help cure illnesses in a variety of ways. However, their low solubility, instability, and fast elimination make them ineffective. As a result, we must address these issues in order to increase the therapeutic effectiveness.

A unique medical therapy with a multi-level and multi-target strategy that is pulmonary drug delivery system (PDDS) which is intended to minimize systemic metabolism and adverse responses of the medicine and to increase drug bioavailability also it solves the present clinical issues with oral and injectable this aid traditional Chinese medicine (TCM) to rapidly gained popularity across the world. The increased incidence of chronic illnesses, technical improvements, and the expansion of the biologics industry are all projected to propel the drug delivery devices market forward throughout the forecast period.

China's population is ageing, and chronic ailments are becoming more common. Since 1970, China's population life expectancy has grown by 17 years. From 2010 to 2040, the proportion of Chinese citizens aged 60 and up is expected to rise from 12.4 percent (168 million) to 28 percent (402 million).

According to WHO, Diabetes affects over 10% of all adults in China, or around 110 million individuals. Diabetes and its consequences account for about 1 million deaths in China each year. This leads to rising demand for auto injectors and wearable injectors device demand. Recently developed technology is transdermal drug delivery has recently progressed from crude approaches that depend only on natural diffusion to dynamic drug release systems that respond to external stimuli. Microneedles have also been used to break through physical barriers in the skin, allowing for regulated distribution via wearable biosensors.

Nanoscale drug delivery systems (NDDS) have rapidly evolved in order to deliver medications to their target sites. NDDS with adjustable drug behaviors on tissues, cells, and organelles can be used to break through multi-stage barriers and manage drug metabolism, in addition to preventing drug degradation and conserving drug physicochemical qualities. 

In August 2021, Weihai Hengyu Medical Products, a Chinese injectable medicine delivery company, has agreed to sell Aptar an 80 percent ownership in the company. Even if China seeks to reduce its reliance on foreign imports, Aptar will be able to access the key market as a result of the purchase.

In July 2018 Zhejiang Yangtze River Delta Biotech Management and   IRISYS, LLC, a San Diego-based contract pharmaceutical product development and manufacturing services provider, announced to signed a memorandum of understanding with to co-build and co-run a new Drug Delivery Systems platform as part of the International Accelerator in Hangzhou, Zhejiang province, China.

Market Trends, Drivers, Restraints, and Opportunities

• Rise in the incidence of cardiovascular illnesses (CVD), demanding the use of long-term medication.
• Development in new generation devices such as portable and wearable are gaining popularity particularly in the home healthcare market.
• Development of novel drug therapies is anticipated to fuel the market even further.
• Increased awareness among population for drug are projected to boost the Italian drug delivery devices market.
• Rising Obesity and diabetes among the urban population leading to heart related issue is the major driver for the market.
• Simplicity, dependability, and the possibility to be administered by the patient directly are fueling the market.
• Unaffordability, lack of or no reimbursements are anticipated to restrain the market.
• Research and development in novel drugs and delivery system are creating a significant opportunity for market player.

Scope of the Report

The report on China drug delivery devices Market the includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

China Drug Delivery Devices Market Segment Insights

The cardiovascular segment is estimated to account for a major market share

Based on route of applications, China drug delivery devices market is divided into cardiovascular, oncology, autoimmune disorder, pulmonary disease, and other. The cardiovascular is expected to represent a key share of the market due to rising aging population and behavioral changes in lifestyles and stroke, pulmonary heart disease, heart failure (HF), rheumatic heart disease, congenital heart disease, coronary heart disease (CHD), and hypertension are major causes of death in the rural Chinese population.

The auto injectors segment is expected to grow at a robust pace

In terms of device type, the China drug delivery devices market is segmented into nasal, injectable, implantable, and others. The injectable segment further segregated into conventional drug delivery devices, and self-injectable drug delivery devices. The self-injectable drug delivery devices are further divided into prefilled syringes, auto injectors, and others. The auto injectors are expected to represent a key share of the market in the coming years due to research advancement and innovative designs, such as portable devices, autoinjectors with two auto injectable doses in one device are driving the market.

The hospitals segment is anticipated to register rapid CAGR

On the basis of end users, the China drug delivery devices market is divided into hospitals, ambulatory surgical centers, and other. The hospitals segment is expected to constitute a key share of the market during the forecast period due to increased elderly population and advancements in pharmaceutical or drug delivery technologies.

Segments

The China drug delivery devices market has been segmented on the basis of

Applications

• Cardiovascular
• Oncology
• Autoimmune Disorder
• Pulmonary Disease
• Other

Device Type

• Nasal
  • Inhalers
  • Other
• Injectable
  • Conventional Drug Delivery Devices
  • Self-injectable Drug Delivery Devices
    • Prefilled Syringes
    • Auto Injectors
    • Others
• Implantable
• Others

 End Users

• Hospitals
• Pharmacy
• Others

Country

• China

Key Players

• F. Hoffmann-La Roche AG
• Becton
• Dickinson and Company
• Teva Pharmaceutical Industries Ltd.
• Gerresheimer AG
• Pfizer Inc

Competitive Landscape

Key players competing in the China drug delivery devices market include F. Hoffmann-La Roche AG; Becton; Dickinson and Company; Teva Pharmaceutical Industries Ltd.; Gerresheimer AG; Pfizer Inc.